PVLA
Palvella Therapeutics Inc.
$125.96
-$2.68(-2.08%)
37
Overall
40
Value
45
Tech
28
Quality
Market Cap
$937.64M
Volume
303.24K
52W Range
$20.20 - $151.18
Target Price
$229.44
Company Overview
| Mkt Cap | $937.64M | Price | $125.96 |
| Volume | 303.24K | Change | -2.08% |
| P/E Ratio | -53.8 | Open | $129.31 |
| Revenue | -- | Prev Close | $128.64 |
| Net Income | $-17.4M | 52W Range | $20.20 - $151.18 |
| Div Yield | N/A | Target | $229.44 |
| Overall | 37 | Value | 40 |
| Quality | 28 | Technical | 45 |
No chart data available
About Palvella Therapeutics Inc.
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.
Latest News
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and Palvella Therapeutics (PVLA)
Howard Kim•a month ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | PVLA | $125.96 | -2.1% | 303.24K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Palvella Therapeutics Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW